218 related articles for article (PubMed ID: 10854429)
1. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.
Gouédard L; Chen YG; Thevenet L; Racine C; Borie S; Lamarre I; Josso N; Massague J; di Clemente N
J Biol Chem; 2000 Sep; 275(36):27973-8. PubMed ID: 10854429
[TBL] [Abstract][Full Text] [Related]
2. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
3. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
4. Components of the anti-Müllerian hormone signaling pathway in gonads.
di Clemente N; Josso N; Gouédard L; Belville C
Mol Cell Endocrinol; 2003 Dec; 211(1-2):9-14. PubMed ID: 14656470
[TBL] [Abstract][Full Text] [Related]
5. AMH signaling: from receptor to target gene.
Visser JA
Mol Cell Endocrinol; 2003 Dec; 211(1-2):65-73. PubMed ID: 14656478
[TBL] [Abstract][Full Text] [Related]
6. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
7. Anti-Müllerian hormone and its receptors.
Josso N; di Clemente N; Gouédard L
Mol Cell Endocrinol; 2001 Jun; 179(1-2):25-32. PubMed ID: 11420127
[TBL] [Abstract][Full Text] [Related]
8. Role of type I receptors for anti-Müllerian hormone in the SMAT-1 Sertoli cell line.
Belville C; Jamin SP; Picard JY; Josso N; di Clemente N
Oncogene; 2005 Jul; 24(31):4984-92. PubMed ID: 15897891
[TBL] [Abstract][Full Text] [Related]
9. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice.
Dutertre M; Gouédard L; Xavier F; Long WQ; di Clemente N; Picard JY; Rey R
Endocrinology; 2001 Sep; 142(9):4040-6. PubMed ID: 11517183
[TBL] [Abstract][Full Text] [Related]
10. Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression.
Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
Mol Cell Endocrinol; 2003 Dec; 211(1-2):15-9. PubMed ID: 14656471
[TBL] [Abstract][Full Text] [Related]
11. Autosomal recessive segregation of a truncating mutation of anti-Müllerian type II receptor in a family affected by the persistent Müllerian duct syndrome contrasts with its dominant negative activity in vitro.
Messika-Zeitoun L; Gouédard L; Belville C; Dutertre M; Lins L; Imbeaud S; Hughes IA; Picard JY; Josso N; di Clemente N
J Clin Endocrinol Metab; 2001 Sep; 86(9):4390-7. PubMed ID: 11549681
[TBL] [Abstract][Full Text] [Related]
12. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone.
di Clemente N; Wilson C; Faure E; Boussin L; Carmillo P; Tizard R; Picard JY; Vigier B; Josso N; Cate R
Mol Endocrinol; 1994 Aug; 8(8):1006-20. PubMed ID: 7997230
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells.
Moore RK; Otsuka F; Shimasaki S
J Biol Chem; 2003 Jan; 278(1):304-10. PubMed ID: 12419820
[TBL] [Abstract][Full Text] [Related]
14. Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells.
Hoshiya Y; Gupta V; Segev DL; Hoshiya M; Carey JL; Sasur LM; Tran TT; Ha TU; Maheswaran S
Mol Cell Endocrinol; 2003 Dec; 211(1-2):43-9. PubMed ID: 14656475
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.
Persson U; Souchelnytskyi S; Franzén P; Miyazono K; ten Dijke P; Heldin CH
J Biol Chem; 1997 Aug; 272(34):21187-94. PubMed ID: 9261125
[TBL] [Abstract][Full Text] [Related]
16. Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family.
Josso N; Clemente Nd
Trends Endocrinol Metab; 2003 Mar; 14(2):91-7. PubMed ID: 12591180
[TBL] [Abstract][Full Text] [Related]
17. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.
Macías-Silva M; Hoodless PA; Tang SJ; Buchwald M; Wrana JL
J Biol Chem; 1998 Oct; 273(40):25628-36. PubMed ID: 9748228
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein-2 and -4 limit the number of enteric neurons but promote development of a TrkC-expressing neurotrophin-3-dependent subset.
Chalazonitis A; D'Autréaux F; Guha U; Pham TD; Faure C; Chen JJ; Roman D; Kan L; Rothman TP; Kessler JA; Gershon MD
J Neurosci; 2004 Apr; 24(17):4266-82. PubMed ID: 15115823
[TBL] [Abstract][Full Text] [Related]
19. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
